Evaluation Improving Outcomes in MDD: Shining a Light on Glutamatergic Therapies Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Rakesh Jain, MD 5 4 3 2 1 Maria Margaglione 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Assess the prevalence and burden of poor response in individuals with MDD 5 4 3 2 1 Discuss the limitations of traditional antidepressants that contribute to poor response in MDD 5 4 3 2 1 Describe the role of glutamatergic signaling in the pathophysiology of MDD and how this translates to potential therapeutic targets 5 4 3 2 1 Evaluate the mechanisms of action, PK profiles, and latest clinical data associated with newer and emerging glutamatergic pharmacotherapies 5 4 3 2 1 Implement therapeutic strategies to incorporate the latest clinical evidence into informed treatment decisions 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with MDD on a weekly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage MDD. Excellent Very Good Good Fair Poor As a result of this activity, I intend to make changes in the following areas as they pertain to the diagnosis/treatment of MDD Carefully consider patient needs/factors when considering MDD treatment options Incorporate novel treatments earlier in the course of disease to maximize potential for symptom relief and improved quality of life Utilize novel glutamatergic therapeutic strategies in appropriate patients with MDD Evaluate the latest clinical trial data to stay informed regarding newer and emerging MDD treatment options Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Previous
